BNT324 in combination with BNT327 for Advanced lung cancer
BioNTech SE(BNTX)
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT06892548 on ClinicalTrials.gov →Study type
interventional
Design
Phase Ib/II, multi-site, open-…
Target enrollment
594
Est. completion
2028-09
Investor scorecard
Probability of success
moderate
Timeline to catalyst
Initial safety and dose-escalation data may be available in 2026, with early efficacy data from expansion cohorts possibly in 2027. Full trial completion is expected by September 2028.
Potential stock impact
SignificantThe combination of two novel biologics is scientifically promising but early-stage. The trial is large (594 patients) for a Phase Ib/II, suggesting BioNTech is investing heavily. However, many combination trials fail due to toxicity or lack of efficacy. The probability of success is moderate, reflecting the potential but also the high risk of early-phase oncology trials.
What is being tested?
This trial is testing a new combination of two experimental drugs, BNT324 and BNT327, in patients with advanced lung cancer. BNT327 is likely a bispecific antibody that targets two proteins on cancer cells to boost the immune system's attack. BNT324 is another biological drug that may target a different pathway to further enhance the anti-cancer effect. The goal is to see if combining them is safe and effective in shrinking tumors or slowing cancer growth. The study is for patients whose lung cancer has advanced and who have limited treatment options.
How does the trial work?
The trial has two parts. Part 1 (dose escalation) enrolls small groups of patients to find the safest dose of the combination. Patients receive the drugs intravenously, likely every few weeks. Doctors monitor for side effects and adjust doses. Once a recommended dose is found, Part 2 (expansion) enrolls more patients in up to 7 cohorts, each targeting specific lung cancer types or prior treatments. Some cohorts are randomized to compare the combination to standard care or other treatments. Patients are followed for tumor response via imaging, side effects, and survival. The study is open-label, meaning both patients and doctors know which treatment is given.
What does success look like?
Success in Part 1 is primarily safety: few severe side effects and a tolerable dose. In Part 2, the key endpoint is objective response rate (ORR) - the percentage of patients with significant tumor shrinkage. For lung cancer, an ORR of 20-30% is often considered promising for advanced disease, but it depends on the specific cohort. Secondary endpoints like progression-free survival (PFS) and overall survival (OS) are also important. For example, if the combination shows a response rate significantly higher than historical controls (e.g., >30%) and a good safety profile, it would be considered a success. The trial will also look for durable responses and improvements in survival.
What it means for investors
For BioNTech, this trial is a significant step in expanding its oncology pipeline beyond its COVID-19 vaccine. Positive results could validate the combination approach and lead to larger Phase III trials, potentially opening a large market in lung cancer. If the trial shows strong efficacy and safety, it could boost investor confidence and stock price. However, early-phase trials have high failure rates, and safety issues or lack of efficacy could cause the stock to drop. Investors should watch for interim data readouts, especially ORR and safety in Part 2. A successful outcome could position BioNTech as a major player in immuno-oncology, while failure might set back their pipeline. The trial is expected to complete by 2028, so catalysts are years away, but interim data may come sooner.
Trial endpoints
Primary endpoints
Secondary endpoints
Comparator
Not specified (open-label, may include standard of care in some cohorts)
Competitive landscape
Lung cancer is the leading cause of cancer death worldwide, with over 2 million new cases annually. The market for lung cancer therapies is projected to exceed $50 billion by 2030. Advanced lung cancer, including non-small cell and small cell, has a high unmet need, especially for patients who progress on standard therapies. Immuno-oncology combinations are a major growth area. If BNT324 + BNT327 shows efficacy in a broad patient population, it could capture a significant share, but competition is intense with many approved and investigational agents.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Tarlatamab (AMG 757) | Amgen | Phase 1 | Targets DLL3 on small cell lung cancer cells, approved for third-line treatment; different mechanism and indication. |
| Lazertinib + Amivantamab | Janssen (Johnson & Johnson) | Phase 1 | Targets EGFR and MET pathways in non-small cell lung cancer with specific mutations; oral + IV combination. |
| Pembrolizumab (Keytruda) | Merck | Phase 1 | PD-1 inhibitor, standard of care for many lung cancers; combination with chemotherapy or other agents. |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1 | PD-1 and CTLA-4 inhibitors, approved for first-line non-small cell lung cancer; different immune targets. |
Historical context
Prior trial results
No prior clinical data for this specific combination is publicly available. BNT327 is likely a bispecific antibody targeting PD-L1 and VEGF, based on BioNTech's pipeline. BNT324 is an investigational agent, possibly targeting another immune checkpoint or tumor antigen. Preclinical data may have shown synergistic anti-tumor activity.
Regulatory history
No regulatory designations (fast track, breakthrough) have been announced for this combination. The trial is in early phase (Ib/II), so regulatory interactions are limited.
Similar drug precedents
Combinations of PD-1/PD-L1 inhibitors with anti-angiogenic agents (like bevacizumab) have shown improved outcomes in lung cancer, e.g., atezolizumab + bevacizumab + chemotherapy. Bispecific antibodies like amivantamab have shown efficacy in EGFR-mutant lung cancer. However, many combinations fail in Phase II/III due to toxicity or lack of benefit. The success of this combination will depend on careful dose selection and patient selection.